Oral Dental pain, Headache, Menorrhagia, Mild to moderate pain, Osteoarthritis, Pain and inflammation associated with musculoskeletal and joint disorders, Postoperative pain, Primary dysmenorrhoea, Rheumatoid arthritis
Adult: 500 mg tid. Child: ≥14 years Same as adult dose. Elderly: Initiate at a lower dose and shortest possible duration.
Should be taken with food.
Hypersensitivity. Patients with active or history of recurrent peptic ulcer/haemorrhage, history of gastrointestinal bleeding or perforation (related to previous NSAID therapy), inflammatory bowel disease, severe heart failure, history of asthma, bronchospasm, rhinitis, angioedema, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Treatment of peri-operative pain in the setting of CABG surgery. Renal (CrCl <30 mL/min) and severe hepatic impairment. Pregnancy (3rd trimester).
Patient with risk factors for CV events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking), mild to moderate heart failure, hypovolaemia, dehydration. Debilitated patient. Renal and hepatic impairment. Elderly. Pregnancy (1st-2nd trimester) and lactation.
Significant: Anaphylactoid reactions, fluid retention, anaemia, hyperkalaemia. Blood and lymphatic system disorders: Eosinophilia, leukopenia, thrombocytopenia, purpura, agranulocytosis. Cardiac disorders: Dyspnoea. Ear and labyrinth disorders: Tinnitus. Gastrointestinal disorders: Diarrhoea, nausea, vomiting, abdominal pain, flatulence, constipation, dyspepsia, heartburn, gastritis. Hepatobiliary disorders: Hepatitis, jaundice. Investigations: Increased liver enzymes. Nervous system disorders: Aseptic meningitis, headache. Psychiatric disorders: Nervousness, insomnia, confusion, depression. Renal and urinary disorders: Dysuria, cystitis. Reproductive system and breast disorders: Haematuria. Respiratory, thoracic and mediastinal disorders: Asthma. Skin and subcutaneous tissue disorders: Pruritus, urticaria, rash, erythema multiforme. Vascular disorders: Hypertension. Potentially Fatal: CV thrombotic events including MI and stroke, gastrointestinal inflammation, bleeding, ulceration, perforation. Rarely, exfoliative dermatitis, toxic epidermal necrolysis, Stevens-Johnson syndrome, fulminant hepatitis, liver necrosis, hepatic failure.
PO: C, D (Avoid during 3rd trimester or near delivery.)
Patient Counseling Information
This drug may cause dizziness, drowsiness, and visual disturbances, if affected, do not drive or operate machinery.
Monitor CBC, chemistry profile, occult blood loss, renal and liver function. Blood pressure should be monitored during initiation of treatment and throughout the course of therapy.
Symptoms: Lethargy, drowsiness, headache, nausea, vomiting, epigastric pain, gastrointestinal bleeding. Rarely, diarrhoea, disorientation, excitation, tinnitus, fainting, hypertension, acute renal failure, respiratory depression, and coma. Management: Symptomatic and supportive treatment. Administer activated charcoal or consider emesis within 4 hours of ingestion of large overdoses.
May increase the risk of bleeding with other NSAIDs or salicylates (e.g. aspirin), anticoagulants (e.g. warfarin), corticosteroids, SSRI. Increased the risk of nephrotoxicity of ciclosporin or tacrolimus. May decrease efficacy of antihypertensive agents (e.g. ACE inhibitors, angiotensin II antagonists, ß-blockers). Decreased natriuretic effect of diuretics (e.g. furosemide, hydrochlorothiazide). Increased plasma levels and reduced renal clearance of lithium. Increased serum concentration of digoxin and methotrexate.
May result to false positive urinary bilirubin in diazo tablet test.
Description: Mefenamic acid, an anthranilic acid derivative, is an NSAID. It reversibly inhibits cyclooxygenase-1 and -2 (COX-1 and -2), thus resulting in reduced rate of prostaglandin synthesis. It exhibits analgesic, anti-inflammatory and antipyretic properties. Pharmacokinetics: Absorption: Rapidly absorbed from the gastrointestinal tract. Time to peak plasma concentration: 2-4 hours. Distribution: Present in breast milk. Volume of distribution: 1.06 L/kg. Plasma protein binding: >90% to albumin. Metabolism: Metabolised in the liver by CYP2C9 isoenzyme to 3-hydroxymethyl mefenamic acid, which may then be oxidised to 3-carboxymefenamic acid. Excretion: Via urine (approx 52%; 6% as glucuronides, 25% as 3-hydroxymefenamic acid, 21% as 3-carboxymefenamic acid), faeces (up to 20%, mainly as unconjugated 3-carboxymefenamic acid). Elimination half-life: Approx 2 hours.
M01AG01 - mefenamic acid ; Belongs to the class of non-steroidal antiinflammatory and antirheumatic products, fenamates.
Anon. Mefenamic Acid. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 28/07/2014.Buckingham R (ed). Mefenamic Acid. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 11/04/2019.Joint Formulary Committee. Mefenamic Acid. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 07/05/2019.McEvoy GK, Snow EK, Miller J et al (eds). Mefenamic Acid. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 28/07/2014.Mefenamic Acid Capsule (Breckenridge Pharmaceutical, Inc.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 11/04/2019.Pfizer New Zealand Ltd. Ponstan Capsules data sheet 29 November 2018. Medsafe. http://www.medsafe.govt.nz/. Accessed 11/04/2019.